Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

COR vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
COR
Cencora, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$50.80B
5Y Perf.+173.8%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$90.21B
5Y Perf.+364.2%

COR vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
COR logoCOR
MCK logoMCK
IndustryMedical - DistributionMedical - Distribution
Market Cap$50.80B$90.21B
Revenue (TTM)$328.68B$403.43B
Net Income (TTM)$2.55B$4.76B
Gross Margin3.5%3.6%
Operating Margin1.2%1.5%
Forward P/E14.7x16.7x
Total Debt$10.75B$8.61B
Cash & Equiv.$4.39B$3.98B

COR vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

COR
MCK
StockMay 20May 26Return
Cencora, Inc. (COR)100273.8+173.8%
McKesson Corporation (MCK)100464.2+364.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: COR vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCK leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Cencora, Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
COR
Cencora, Inc.
The Income Pick

COR is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • Dividend streak 24 yrs, beta 0.00, yield 0.9%
  • Lower volatility, beta 0.00, current ratio 0.90x
  • Beta 0.00, yield 0.9%, current ratio 0.90x
Best for: income & stability and sleep-well-at-night
MCK
McKesson Corporation
The Growth Play

MCK carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 12.4%, EPS growth 49.2%, 3Y rev CAGR 13.4%
  • 339.0% 10Y total return vs COR's 276.7%
  • 12.4% revenue growth vs COR's 9.3%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK12.4% revenue growth vs COR's 9.3%
ValueCOR logoCORLower P/E (14.7x vs 16.7x)
Quality / MarginsMCK logoMCK1.2% margin vs COR's 0.8%
Stability / SafetyMCK logoMCKLower D/E ratio (109.6% vs 6.2%)
DividendsCOR logoCOR0.9% yield, 24-year raise streak, vs MCK's 0.4%
Momentum (1Y)MCK logoMCK+7.2% vs COR's -7.2%
Efficiency (ROA)MCK logoMCK5.7% ROA vs COR's 3.3%, ROIC 74.5% vs 44.5%

COR vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CORCencora, Inc.
FY 2025
Pharmaceutical Distribution
88.8%$285.3B
International Healthcare Solutions
9.4%$30.4B
Animal Health
1.8%$5.7B
MCKMcKesson Corporation
FY 2026
North American Pharmaceutical Segment
83.4%$336.7B
Oncology And Multispecialty Segment
12.0%$48.4B
Medical-Surgical Solutions Segment
2.9%$11.5B
Prescription Technology Solutions Segment
1.4%$5.8B
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
0.3%$1.0B

COR vs MCK — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMCKLAGGINGCOR

Income & Cash Flow (Last 12 Months)

MCK leads this category, winning 5 of 6 comparable metrics.

MCK and COR operate at a comparable scale, with $403.4B and $328.7B in trailing revenue. Profitability is closely matched — net margins range from 1.2% (MCK) to 0.8% (COR).

MetricCOR logoCORCencora, Inc.MCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$328.7B$403.4B
EBITDAEarnings before interest/tax$5.0B$6.8B
Net IncomeAfter-tax profit$2.5B$4.8B
Free Cash FlowCash after capex$1.6B$6.0B
Gross MarginGross profit ÷ Revenue+3.5%+3.6%
Operating MarginEBIT ÷ Revenue+1.2%+1.5%
Net MarginNet income ÷ Revenue+0.8%+1.2%
FCF MarginFCF ÷ Revenue+0.5%+1.5%
Rev. Growth (YoY)Latest quarter vs prior year+3.8%+6.0%
EPS Growth (YoY)Latest quarter vs prior year+128.3%+37.0%
MCK leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

Evenly matched — COR and MCK each lead in 3 of 6 comparable metrics.

At 19.2x trailing earnings, MCK trades at a 41% valuation discount to COR's 32.8x P/E. On an enterprise value basis, COR's 12.1x EV/EBITDA is more attractive than MCK's 15.3x.

MetricCOR logoCORCencora, Inc.MCK logoMCKMcKesson Corporat…
Market CapShares × price$50.8B$90.2B
Enterprise ValueMkt cap + debt − cash$57.1B$94.9B
Trailing P/EPrice ÷ TTM EPS32.80x19.19x
Forward P/EPrice ÷ next-FY EPS est.14.74x16.66x
PEG RatioP/E ÷ EPS growth rate0.43x
EV / EBITDAEnterprise value multiple12.14x15.27x
Price / SalesMarket cap ÷ Revenue0.16x0.22x
Price / BookPrice ÷ Book value/share29.17x11.63x
Price / FCFMarket cap ÷ FCF15.84x14.66x
Evenly matched — COR and MCK each lead in 3 of 6 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 9 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $106 for COR. MCK carries lower financial leverage with a 1.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to COR's 6.15x. On the Piotroski fundamental quality scale (0–9), MCK scores 7/9 vs COR's 6/9, reflecting strong financial health.

MetricCOR logoCORCencora, Inc.MCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity+105.8%+3.0%
ROA (TTM)Return on assets+3.3%+5.7%
ROICReturn on invested capital+44.5%+74.5%
ROCEReturn on capital employed+23.1%+43.1%
Piotroski ScoreFundamental quality 0–967
Debt / EquityFinancial leverage6.15x1.10x
Net DebtTotal debt minus cash$6.4B$4.6B
Cash & Equiv.Liquid assets$4.4B$4.0B
Total DebtShort + long-term debt$10.7B$8.6B
Interest CoverageEBIT ÷ Interest expense3.73x33.79x
MCK leads this category, winning 9 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MCK leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $37,043 today (with dividends reinvested), compared to $22,002 for COR. Over the past 12 months, MCK leads with a +7.2% total return vs COR's -7.2%. The 3-year compound annual growth rate (CAGR) favors MCK at 26.4% vs COR's 16.7% — a key indicator of consistent wealth creation.

MetricCOR logoCORCencora, Inc.MCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date-22.8%-10.5%
1-Year ReturnPast 12 months-7.2%+7.2%
3-Year ReturnCumulative with dividends+59.0%+102.1%
5-Year ReturnCumulative with dividends+120.0%+270.4%
10-Year ReturnCumulative with dividends+276.7%+339.0%
CAGR (3Y)Annualised 3-year return+16.7%+26.4%
MCK leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

MCK leads this category, winning 2 of 2 comparable metrics.

MCK is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than COR's 0.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MCK currently trades 73.7% from its 52-week high vs COR's 69.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCOR logoCORCencora, Inc.MCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5000.00x-0.02x
52-Week HighHighest price in past year$377.54$999.00
52-Week LowLowest price in past year$244.82$637.00
% of 52W HighCurrent price vs 52-week peak+69.2%+73.7%
RSI (14)Momentum oscillator 0–10019.521.0
Avg Volume (50D)Average daily shares traded1.5M782K
MCK leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

COR leads this category, winning 2 of 2 comparable metrics.

Wall Street rates COR as "Buy" and MCK as "Buy". Consensus price targets imply 54.5% upside for COR (target: $403) vs 35.1% for MCK (target: $995). For income investors, COR offers the higher dividend yield at 0.86% vs MCK's 0.42%.

MetricCOR logoCORCencora, Inc.MCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$403.29$994.86
# AnalystsCovering analysts4631
Dividend YieldAnnual dividend ÷ price+0.9%+0.4%
Dividend StreakConsecutive years of raises2418
Dividend / ShareAnnual DPS$2.24$3.07
Buyback YieldShare repurchases ÷ mkt cap+0.9%0.0%
COR leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

MCK leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). COR leads in 1 (Analyst Outlook). 1 tied.

Best OverallMcKesson Corporation (MCK)Leads 4 of 6 categories
Loading custom metrics...

COR vs MCK: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is COR or MCK a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 12.

4% revenue growth year-over-year, versus 9. 3% for Cencora, Inc. (COR). McKesson Corporation (MCK) offers the better valuation at 19. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Cencora, Inc. (COR) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — COR or MCK?

On trailing P/E, McKesson Corporation (MCK) is the cheapest at 19.

2x versus Cencora, Inc. at 32. 8x. On forward P/E, Cencora, Inc. is actually cheaper at 14. 7x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — COR or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +270.

4%, compared to +120. 0% for Cencora, Inc. (COR). Over 10 years, the gap is even starker: MCK returned +339. 0% versus COR's +276. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — COR or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus Cencora, Inc. 's 0. 00β — meaning COR is approximately -118% more volatile than MCK relative to the S&P 500. On balance sheet safety, McKesson Corporation (MCK) carries a lower debt/equity ratio of 110% versus 6% for Cencora, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — COR or MCK?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 12.

4% versus 9. 3% for Cencora, Inc. (COR). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 49. 2% year-over-year, compared to 5. 7% for Cencora, Inc.. Over a 3-year CAGR, MCK leads at 13. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — COR or MCK?

McKesson Corporation (MCK) is the more profitable company, earning 1.

2% net margin versus 0. 5% for Cencora, Inc. — meaning it keeps 1. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 5% versus 1. 1% for COR. At the gross margin level — before operating expenses — MCK leads at 3. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is COR or MCK more undervalued right now?

On forward earnings alone, Cencora, Inc.

(COR) trades at 14. 7x forward P/E versus 16. 7x for McKesson Corporation — 1. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COR: 54. 5% to $403. 29.

08

Which pays a better dividend — COR or MCK?

All stocks in this comparison pay dividends.

Cencora, Inc. (COR) offers the highest yield at 0. 9%, versus 0. 4% for McKesson Corporation (MCK).

09

Is COR or MCK better for a retirement portfolio?

For long-horizon retirement investors, Cencora, Inc.

(COR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 00), 0. 9% yield, +276. 7% 10Y return). Both have compounded well over 10 years (COR: +276. 7%, MCK: +339. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between COR and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

COR pays a dividend while MCK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

COR

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform COR and MCK on the metrics below

Revenue Growth>
%
(COR: 3.8% · MCK: 6.0%)
P/E Ratio<
x
(COR: 32.8x · MCK: 19.2x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.